PubMed · 15806863
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
H K Biesalski. 2003. Nutritargeting.. https://pubmed.ncbi.nlm.nih.gov/15806863/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Absorption of hydrogen sulfide in aqueous suspensions of biologically produced sulfur particles was studied in a batch stirred cell reactor, and in a continuous set-up, consisting of a lab-scale gas absorber column and a bioreactor. Presence of biosulfur particles was found to enhance the absorption rate of H(2)S gas in the mildly alkaline liquid. The mechanism for this enhancement was however found to depend on the type of particles used. In the gently stirred cell reactor only small hydrophilic particles were present (d(p) < 3 microm) and the enhancement of the H(2)S absorption rate can be explained from the heterogeneous reaction between dissolved H(2)S and solid elemental sulfur to polysulfide ions, S(x) (2-). Conditions favoring enhanced H(2)S absorption for these hydrophilic particles are: low liquid side mass transfer (k(L)), high sulfur content, and presence of polysulfide ions. In the set-up of gas absorber column and bioreactor, both small hydrophilic particles and larger, more hydrophobic particles were continuously produced (d(p) up to 20 microm). Here, observed enhancement could not be explained by the heterogeneous reaction between sulfide and sulfur, due to the relatively low specific particle surface area, high k(L), and low [S(x) (2-)]. A more likely explanation for enhancement here is the more hydrophobic behavior of the larger particles. A local increase of the hydrophobic sulfur particle concentration near the gas/liquid interface and specific adsorption of H(2)S at the particle surface can result in an increase in the H(2)S absorption rate.
Cytokines are implicated in the anaemia of chronic disease by reducing erythropoiesis and increasing iron sequestration in the reticuloendotheial system. However, the effect of cytokines, in particular TNFalpha (tumour necrosis factor alpha), on small bowel iron uptake and iron-transporter expression remains unclear. In the present study, we subjected CD1 male mice to intraperitoneal injection with TNFalpha (10 ng/mouse) and then examined the expression and localization of DMT1 (divalent metal transporter 1), IREG1 (iron-regulated protein 1) and ferritin in duodenum. Liver and spleen samples were used to determine hepcidin mRNA expression. Changes in serum iron and iron loading of duodenum, spleen and liver were also determined. We found a significant (P<0.05) fall in serum iron 3 h post-TNFalpha exposure. This was coincident with increased iron deposition in the spleen. After 24 h of exposure, there was a significant decrease in duodenal iron transfer (P<0.05) coincident with increased enterocyte ferritin expression (P<0.05) and re-localization of IREG1 from the basolateral enterocyte membrane. Hepatic hepcidin mRNA levels remained unchanged, whereas splenic hepcidin mRNA expression was reduced at 24 h. In conclusion, we provide evidence that TNFalpha may contribute to anaemia of chronic disease by iron sequestration in the spleen and by reduced duodenal iron transfer, which seems to be due to increased enterocyte iron binding by ferritin and a loss of IREG1 function. These observations were independent of hepcidin mRNA levels.
BACKGROUND: Alicaforsen is a phosphorothioate-modified antisense oligodeoxynucleotide designed to sequence-specifically reduce intercellular adhesion molecule 1 messenger RNA levels. AIMS: To determine the systemic and local bioavailability of alicaforsen, and its activity when administered as a once daily enema in subjects with active ulcerative colitis. METHODS An open-label study was conducted to assess the relative absorption (local and systemic pharmacokinetics) and pharmacologic activity of alicaforsen enema in subjects with active ulcerative colitis. Fifteen subjects received nightly enemas of alicaforsen (240 mg) for a treatment period of 6 weeks. Alicaforsen concentrations in plasma and colonic tissue biopsies were determined. Disease activity index and multiple measurements including endoscopy were used to assess alicaforsen activity in these subjects. RESULTS: Plasma concentrations of parent alicaforsen represented < 0.6% mean bioavailability when compared with historical intravenous area under the plasma concentration-time curves. Concentrations of the intact oligonucleotide in mucosal colonic tissue biopsies were orders of magnitude higher than those observed in plasma. A 46% reduction in mean Disease Activity Index and 33% rate of remission as defined by complete mucosal healing were observed at the end of treatment. Conclusion These data confirm that alicaforsen enema provides local treatment for a local disease with little meaningful systemic exposure.